This document discusses infertility investigations and treatments. It recommends referring couples for investigations after 1 year of unprotected sex if the woman is under 36, or earlier if she is over 36 or there is a known cause of infertility. Common causes of infertility include male factors, female tubal issues, ovulatory disorders, and unexplained causes. Recommended initial investigations include a semen analysis, HSG, and progesterone test. Treatments discussed include IVF for moderate to severe tubal disease or other complicating factors, and laparoscopic surgery for mild tubal disease. The document provides guidance on investigating and treating various conditions that may cause infertility such as PCOS, hyperprolactinemia, and ovarian failure.
2. When to refer a couple for
investigations?
Not conceived with unprotected sexual
intercourse
Age <36 y
Absence of any known cause of infertility
After one year
Age >36 y
known clinical cause of infertility
history of predisposing factors for infertility
Earlier
Aboubakr Elnashar
3. Incidence
1 in 7 couples
Main causes
Male factors: 30%
Female: 45%
• Tubal: 20%
• Ovulatory disorders: 25%
• Uterine: 10%
• Endometriosis: 5%
Unexplained: 25%
Combined male and female: 40%
Aboubakr Elnashar
4. Investigations
(ESHRE, 2000)
I. Tests that have an established association
with pregnancy:
Conventional semen analysis
HSG
Midluteal progesterone
Aboubakr Elnashar
5. II. Tests that are not consistently associated
with pregnancy:
Post-coital test
Antisperm antibody tests
Zona-free hamster egg penetration test
III. Tests that have no association with
pregnancy:
Endometrial biopsy
Varicocele assessment
Chlamydia testing
Aboubakr Elnashar
7. Investigations
1. HSG
No co morbidities:
PID
Previous ectopic pregnancy or
Endometriosis
{reliable test for ruling out tubal occlusion
less invasive
makes more efficient use of resources than
laparoscopy}
Aboubakr Elnashar
10. HS-contrast-US
Free fluid collection in the cul-de-sac following
successful demonstration of oviductal patency.
Oviductal fimbria are clearly observed in the collected
fluid.
Aboubakr Elnashar
11. 2. Laparoscopy and dye test
Co morbidities
{tubal and other pelvic pathology can be assessed
at the same time}.
Aboubakr Elnashar
12. 3. Hysteroscopy
Not an initial investigation unless clinically indicated
{effectiveness of surgical treatment of uterine
abnormalities on improving pregnancy rates has not
been established}.
Aboubakr Elnashar
13. Classification of Tubal disease
British Fertility Society
Minor
Proximal occlusion
without tubal fibrosis
Distal occlusion without
tubal distension
Healthy mucosal
appearance at HSG,
salpingoscopy
Flimsy peritubal/ovarian
adhesions.
Intermediate
Unilateral
severe tubal
damage
Limited dense
adhesions of
tubes & ovaries
Severe
Bilateral severe tubal
damage
Extensive tubal fibrosis
Tubal distension >1.5 cm
Abnormal mucosal
appearance
Bipolar occlusion
Extensive dense adhesion
Aboubakr Elnashar
18. III. Selective salpingography plus tubal
catheterisation, or hysteroscopic tubal
cannulation
Proximal tubal disease
If pregnancy has not occurred within 12 mo
of surgery: IVF
Aboubakr Elnashar
20. Investigations
1. Midluteal progesterone
in regular and irregular cycles
{confirm ovulation}
In irregular prolonged cycles
Depending upon the timing of menstrual periods, conducted later in
the cycle (for example day 28 of a 35-day cycle) and repeated
weekly thereafter until the next menstrual cycle starts
2. Basal FSH and LH
• Only in
irregular prolonged cycles
Aboubakr Elnashar
21. 3. Prolactin
Only in
ovulatory disorder
galactorrhoea or
pituitary tumour
4. TSH:
only if
symptoms of thyroid disease
Endometrial biopsy
To evaluate the luteal phase: No
{no evidence that medical tt of luteal phase defect
improves pregnancy rates]
Aboubakr Elnashar
22. 5. Ovarian reserve testing
Woman’s age:
An initial predictor of overall chance of success
through natural conception or with IVF
Predictors of ovarian response to Gnt stimulation
in IVF:
High responseLow response
16 or more4 or lessTotal AFC
3.5 or more
25
0.8 or less
5.5
AMH
ng/ml
pmol/l
Conversion ratio:7
4 or less8.9 or moreFSH IU/L
Aboubakr Elnashar
23. • Do not use
1. ovarian volume
2. ovarian blood flow
3. inhibin B
4. E2
Aboubakr Elnashar
24. WHO: I. Hypothalamic pituitary failure
II. Hypothalamic pituitary dysfunction
III. Ovarian failure
Aboubakr Elnashar
25. Amenorrhea or severe oligomenorrhea
FSH & LH: low
Prolactin: normal
Aboubakr Elnashar
26. 1. Reverse the life style factors:
Increase wt if BMI <19
Moderating exercise if high levels of
exercise.
Treat stress
2. Gonadotrphins with LH activity or
Pulsatile GnRH (pump)
CC:
not effective
Aboubakr Elnashar
27. PCOS
2 of 3 (Noterdam definition,2003):
•U/S PCO
•Hyperandrogenism (Clinical or Laboratory)
•Irregular or absent ovulation
Aboubakr Elnashar
29. OVULATION INDUCTION IN PCOS
NICE, 2013
1. Weigh loss:
If BMI >30 K/m2
alone may restore ovulation
improve response to ovulation induction agents,
positive impact on pregnancy outcomes
Aboubakr Elnashar
30. 2. One of the following taking into account
•potential adverse effects
•ease and mode of use
•BMI
•monitoring needed:
CC: (not more than 6 m) or
Metformin or
CC + Metformin
Aboubakr Elnashar
31. 3. CC resistance:
one of the following 2nd line tt, depending on
•clinical circumstances
•woman's preference:
CC and met if not already offered as1st line tt or
LOD or
Gnt
US monitoring
{measure follicular size and number {reduce the risk
of multiple pregnancy and OHSS}
Aboubakr Elnashar
33. Hyperprolactinaemia
I. Idiopathic
.Dopamine agonist (anxiety, pregnancy ).
Stop during pregnancy
II. Microadenoma
. Dopamine agonist (anxiety, pregnancy).
Stop after 2-3 yr.
. Surgery (rapid growth).
III. Macroadenoma
. Dopamine agonist: long term
. Surgery
(No response, suprasellar extension, pregnancy).Aboubakr Elnashar
35. POF.
Only the stroma of the ovary is identified.
A very few follicles of less than 1 mm on the inferior aspect of
the ovary.
Aboubakr Elnashar
36. 1. Oral contraceptive suppression of gonadotrpins
followed by discontinuation to allow a rebound in
gonadotropins & ovarian function.
2. GnRH agonist suppression of gonadotropins
secretion followed by high dose gonadotropin
injection
3. Glucocorticoids suppression of immune system.
Non of these tts has demonstrated efficacy in RCT
(van Kastren et al, 1995)
Aboubakr Elnashar
40. Infertility workup
1. Ovarian reserve 2. Semen
analysis
3. F tubes
Compromised:
IVF
Not compromised: surgery
Allow 6-18 month
No pregnancy: IVF
No surgery before IVF
except:
Large endometrioma ,
hydrosalpinx,
pelvic pain
de Ziegler et al, 2010Aboubakr Elnashar
41. I. Minimal and mild
(Aboulghar,2003):
• Medical treatment does not enhance
fertility & should not be offered
• Expectant treatment.
• ±COH/IUI.
• Surgical ablation*
• IVF.
*Minimal or mild endometriosis who undergo
laparoscopy should be offered surgical
ablation or resection of endometriosis
plus laparoscopic adhesiolysis
• {improves the chance of pregnancy}.
Aboubakr Elnashar
42. II. Moderate & severe
• IVF:
Treatment of choice (Aboulghar, 2003).
• Postoperative medical treatment
does not improve pregnancy rate & not
recommended
Moderate or severe:
surgical treatment {improves the chance of
pregnancy}.
Aboubakr Elnashar
46. Myomectomy:
-Indications:
1. Distorting the uterine cavity
Submucous:
interfere with fertility and should be removed in infertile
patients, regardless of the size or presence of symptoms
(Gambadauro,2012).
Intramural:
distorting: reduce the chances of conception
not distorting: controversial results.
Subserosal:
No evidence supports removal in asymptomatic, infertile
3. >5-7cm
4. Multiple >3 (3-5 cm)
(Bajekal & Li, 2000)
Aboubakr Elnashar
48. Intramural fibroid
Examples of fibroids which
compromise the contours of the
endometrial cavity.
Refraction artifacts {tissue
density interfaces and the
texture of the fibroids} often aid
in their identification.
Aboubakr Elnashar
50. A. Open myomectomy
(Bajekal & Li, 2000)
The route of choice:
Large SS or IM(>7 cm)
Multiple fibroids (>5)
When entry into uterine cavity is to be
expected
Aboubakr Elnashar
51. B. Hysteroscopic myomectomy:
The route of choice:
SM fibroids.
Compared to laparotomy, it is associated with a
lower risk of scar rupture & no pelvic
adhesion (Bajekal & Li, 2000)
Large (>5 cm) type II SM fibroids may be
unsuitable for hysteroscopic surgery.
A significant benefit of removing SM fibroid
>2cm (Varasteh et al, 1999)Aboubakr Elnashar
53. C. Laparoscopic myomectomy:
Pedunculated or SS: not candidate for removal {not
the cause of infertility or recurrent miscarriage}
(Bajekal & Li, 2000).
IM:
Very experienced laparoscopic surgeon
Uterine rupture: 2 reports both at 34 w
{inability to effectively close the myometrium
laparoscopically}
Uterine indentation
Uterine fistula Aboubakr Elnashar
55. 2. Septate uterus
Not increased among women with infertility
compared with other women (2–3%).
More common: RM or PTL.
Hysteroscopic metroplasty:
No increase pregnancy rates in women with
infertility [Evidence level 2b–3]
Aboubakr Elnashar
57. 3. Intrauterine adhesions
with amenorrhoea
hysteroscopic adhesiolysis
{restore menstruation and improve the chance
of pregnancy}. (C)
Aboubakr Elnashar
60. Inability to conceive after one year with
routine (standard, basic) investigations of
infertility showing no abnormality.
(RCOG guidelines,1998; Randolph,2000)
Dependent on:
Availability of resources ,
Patients’ age
Duration of infertility.
IUI:
ESHRE (2004)
indicated as empiric treatment
Aboubakr Elnashar
62. Cochrane (2012)
• IUI with OH increases the live birth rate compared
to IUI alone.
• The likelihood of pregnancy was also increased
for treatment with IUI compared to TI in stimulated
cycles
Aboubakr Elnashar
63. • NICE, 2013
Do not offer oral ovarian stimulation agents
(such as clomifene citrate, or letrozole).
{no increase the chances of a pregnancy or a live
birth}.
Offer IVF after 2 years
IUI:
when social, cultural or religious objections to
IVF
without stimulation: no better than
expectant management.
with stimulation: better than expectant
management Aboubakr Elnashar